Keystone Heart Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Keystone Heart Ltd.
US-Listed China Biotechs Tank As Xi Takes Third Term
Chinese biotechs listed in the US have a watershed day, with many shares nosediving by over 10% amid leadership changes in China, where the retirement of several economic pragmatists appears to be adding to souring investment sentiment amid views on rising uncertainties and risks.
Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects
Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.
Venus Continues To Drive TAVR In China By Licensing In Australian Start-Up Tech
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.